Scribe Therapeutics
Biotechnology ResearchCalifornia, United States51-200 Employees
Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.
Insights
Key Personnel Updates Scribe Therapeutics recently made significant additions to its leadership team by appointing Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, along with hiring Dr. Maria Mirotsou as Vice President of Discovery Biology. Leveraging the expertise of these key personnel could open opportunities for strategic collaborations and partnerships in the biotechnology industry.
Strategic Partnerships Scribe Therapeutics has established partnerships with notable companies like Sonafi and Prevail Therapeutics, which can serve as entry points for potential sales opportunities. Leveraging these existing relationships, Scribe can explore avenues for expanding its product offerings and reaching new markets within the biotechnology research sector.
Innovation in CRISPR Technology With a focus on developing specialized CRISPR proteins like CasX, Scribe Therapeutics is at the forefront of innovation in genetic medicine. This technological advancement presents a unique value proposition that could attract partnerships with pharmaceutical companies seeking cutting-edge solutions. Sales representatives can leverage Scribe’s CRISPR expertise to engage with potential clients looking to enhance their therapeutic offerings.
Expansion into Neurological Therapies The collaboration between Scribe Therapeutics and Prevail Therapeutics to develop in vivo CRISPR-based therapies for neurological and neuromuscular diseases signals a strategic move into a high-demand segment of the healthcare market. This expansion presents a prime sales opportunity for Scribe to position its advanced therapies as innovative solutions for addressing unmet medical needs in neurology.
Competitive Intelligence Understanding the competitive landscape in the biotechnology research industry and analyzing similar companies like ElevateBio, Mammoth Biosciences, and Beam Therapeutics can provide valuable insights for sales professionals. By identifying gaps in the market and leveraging Scribe’s unique offerings, sales teams can tailor their approach to differentiate the company and capitalize on emerging sales opportunities.
Similar companies to Scribe Therapeutics
ElevateBio
570
$50M$100MMammoth Biosciences
189$10M$50MAro Biotherapeutics
50$10MBeam Therapeutics
504$100M$1BPairwise
119$10M$50MInscripta
26Metagenomi
241$10M$50M
Scribe Therapeutics Tech Stack
Scribe Therapeutics uses 8 technology products and services including Databricks, Amazon Redshift, MySQL, and more. Explore Scribe Therapeutics's tech stack below.
- DatabricksBig Data Processing
- Amazon RedshiftData Warehousing
- MySQLDatabase
- gitDevelopment
- NetSuite ERPEnterprise Resource Planning
- AOSJavascript Libraries
- LinuxProgramming Languages
- PythonProgramming Languages
Media & News
Scribe Therapeutics's Email Address Formats
Scribe Therapeutics uses at least 1 format(s):
| Scribe Therapeutics Email Formats | Percentage |
| FLast@scribetx.com | 75% |
| First@scribetx.com | 22% |
| First.Last@scribetx.com | 2% |
| Last@scribetx.com | 1% |
Frequently Asked Questions
Where is Scribe Therapeutics's headquarters located?
Scribe Therapeutics's main headquarters is located at 1150 Marina Village Pkwy Alameda, CA 94501 US. The company has employees across 3 continents, including North AmericaEuropeAfrica. What is Scribe Therapeutics's official website and social media links?
Scribe Therapeutics's official website is scribetx.com and has social profiles on LinkedIn.How much revenue does Scribe Therapeutics generate?
As of August 2024, Scribe Therapeutics's annual revenue reached $15M. What is Scribe Therapeutics's SIC code NAICS code?
Scribe Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).How many employees does Scribe Therapeutics have currently?
As of August 2024, Scribe Therapeutics has approximately 125 employees across 3 continents, including North AmericaEuropeAfrica. Key team members include Chief Business Officer: S. L.Chief Scientific Officer: A. K.Chief Financial Officer: D. P.. Explore Scribe Therapeutics's employee directory with LeadIQ.What industry does Scribe Therapeutics belong to?
Scribe Therapeutics operates in the Biotechnology Research industry. What technology does Scribe Therapeutics use?
Scribe Therapeutics's tech stack includes DatabricksAmazon RedshiftMySQLgitNetSuite ERPAOSLinuxPython. What is Scribe Therapeutics's email format?
Scribe Therapeutics's email format typically follows the pattern of . Find more Scribe Therapeutics email formats with LeadIQ. 
Company Overview
- Headquarters
- 1150 Marina Village Pkwy Alameda, CA 94501 US
- Website
- scribetx.com
- SIC Code
- 8733 - Noncommercial Research Organizations
- NAICS Code
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Employees
- 51-200
Funding & Financials
- $10M$50M
Scribe Therapeutics's revenue is in the range of $10M$50M
Funding & Financials
- $10M$50M
Scribe Therapeutics's revenue is in the range of $10M$50M
Company Leadership
S. L.Chief Business Officer
A. K.Chief Scientific Officer- D. P.Chief Financial Officer
- K. O. B.Vice President Translational Sciences
- S. S.Vice President Process Science
Employee Directory
D. S.Co-Founder- K. O. B.Vice President Translational Sciences
- V. S.Vice President, Talent
- K. H.Senior Scientist, Tech Platform, Head Of High-Throughput Assay Process And Automation
- S. M.Vp, Program Management
1-888-653-2347 
support@leadiq.com © LeadIQ, Inc. All rights reserved.
